Akero Therapeutics Inc’s filing revealed that its President and CEO Cheng Andrew unloaded Company’s shares for reported $1.62 million on Oct 10 ’25. In the deal valued at $53.98 per share,30,000 shares were sold. As a result of this transaction, Cheng Andrew now holds 526,114 shares worth roughly $28.54 million.
Then, Rolph Timothy sold 12,500 shares, generating $576,001 in total proceeds. Upon selling the shares at $46.08, the Chief Scientific Officer now owns 166,571 shares.
Before that, Timothy Rolph bought 56,369 shares. Akero Therapeutics Inc shares valued at $2,595,229 were divested by the Officer at a price of $46.04 per share.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. BofA Securities also remained covering AKRO and has increased its forecast on January 30, 2025 with a “Buy” recommendation from previously “Neutral” rating. H.C. Wainwright maintained its rating on January 27, 2025. It rated AKRO as “a Buy”.
Price Performance Review of AKRO
On Tuesday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 0.20% to $54.25. Over the last five days, the stock has gained 0.41%. Akero Therapeutics Inc shares have risen nearly 55.58% since the year began. Nevertheless, the stocks have risen 95.00% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $21.34 was recorded on 01/14/25.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 54.13, which if violated will result in even more drops to 54.00. On the upside, there is a resistance level at 54.34. A further resistance level may holdings at 54.42.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-10-31, dropping by -5.55 million shares to a total of 4.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 9.96 million shares. There was a decline of -125.82%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 18, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
